60 citations,
May 2015 in “Archives of dermatological research” PPAR agonists show promise for skin conditions but need more research before being a main treatment.
38 citations,
January 2017 in “PPAR Research” PPAR-γ helps control skin oil glands and inflammation, and its disruption can cause hair loss diseases.
3 citations,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
July 2022 in “Research Square (Research Square)” Lower PPARγ levels and specific gene variations are linked to more severe Frontal Fibrosing Alopecia.
84 citations,
February 2015 in “Experimental Dermatology” PPARγ is crucial for skin health but can have both beneficial and harmful effects.